Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Check out the exclusive pitch deck Valerie Health used to raise $30 million from Redpoint Ventures to automate healthcare faxes - 2Want to be better about saving money in 2026? Try these money-saving tips for having a ‘low-buy’ January and beyond
- 3Fisherman Attacked by Great White Shark Says ‘My Left Foot Was in His Mouth’
- 4Artemis II astronauts race to set a new distance record from Earth and behold the moon's far side
- 5Haunting Giant Squid Surfaces in Japan and Devours Its Prey (Video)
- Human evolution’s biggest mystery has started to unravel. How 2025 tipped the scales
- The Main 15 Powerful Business Heads of Today
- Who is behind Al-Majd, the Israeli-linked evacuation group sending Gazans to South Africa?
- Tyler Childers' 'Snipe Hunt' 2026 Tour: How to get tickets, presale times, prices and more
- Plane Passenger Allegedly Includes ‘Bomb Threat’ in Hotspot Network Name, Forces Flight to Make Emergency Landing
- Novo and Lilly cut prices of weight-loss drugs in China
- The most effective method to Go with Informed Choices on Vehicle Leases
- See the first close-up photos of the moon from NASA's Artemis II mission
- France honors the victims of the Paris attacks' night of terror 10 years on
